sábado, 3 de octubre de 2015

Naltrexona y fibromialgia/Nalrexone for fibromyalgi

Octubre 3, 2015. No. 2103
Anestesia y Medicina del Dolor

Dosis bajas de naltrexona como un nuevo tratamiento anti-inflamatorio en dolor crónico
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15.
Abstract
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
Los síntomas de fibromialgia se reducen con dosis bajas de naltrexona. Estudio piloto
Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
Pain Med. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x. Epub 2009 Apr 22.
Abstract
OBJECTIVE: Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia. DESIGN: Participants completed a single-blind, crossover trial with the following time line: baseline (2 weeks), placebo (2 weeks), drug (8 weeks), and washout (2 weeks). PATIENTS:
Ten women meeting criteria for fibromyalgia and not taking an opioid medication. INTERVENTIONS: Naltrexone, in addition to antagonizing opioid receptors on neurons, also inhibits microglia activity in the central nervous system. At low doses (4.5 mg), naltrexone may inhibit the activity of microglia and reverse central and peripheral inflammation. OUTCOME MEASURES: Participants completed reports of symptom severity everyday, using a handheld computer. In addition, participants visited the lab every 2 weeks for tests of mechanical, heat, and cold pain sensitivity. RESULTS: Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone.
CONCLUSIONS: We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.
  
Efectos de la naltrexona en la sensibilidad al dolor y el estado de humor en la fibromialgia: no hay evidencia de fisiopatología opioide endógena.
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
PLoS One. 2009;4(4):e5180. doi: 10.1371/journal.pone.0005180. Epub 2009 Apr 13.
Abstract
The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.
PDF 
Modulo CEEA Leon, Gto. Curso CEEA Tijuana  XII Congreso Virtual Mexicano de Anestesiologia

          
Anestesiología y Medicina del Dolor
52 664 6848905
vwhizar@anestesia-dolor.org
anestesia-dolor.org

Copyright © 2015

viernes, 2 de octubre de 2015

Diabetes y cirugía / Surgery and diabetes

Octubre 2, 2015. No. 2102
Anestesia y Medicina del Dolor

Manejo perioperatorio del paciente quirúrgico con diabetes 2015.
Peri-operative management of the surgical patient with diabetes 2015: Association of Anaesthetists of Great Britain and Ireland.
Anaesthesia. 2015 Sep 29. doi: 10.1111/anae.13233. [Epub ahead of print]
Abstract
Diabetes affects 10-15% of the surgical population and patients with diabetes undergoing surgery have greater complication rates, mortality rates and length of hospital stay. Modern management of the surgical patient with diabetes focuses on: thorough pre-operative assessment and optimisation of their diabetes (as defined by a HbA1c < 69 mmol.mol-1 ); deciding if the patient can be managed by simple manipulation of pre-existing treatment during a short starvation period (maximum of one missed meal) rather than use of a variable-rate intravenous insulin infusion; and safe use of the latter when it is the only option, for example in emergency patients, patients expected not to return to a normal diet immediately postoperatively, and patients with poorly controlled diabetes. In addition, it is imperative that communication amongst healthcare professionals and between them and the patient is accurate and well informed at all times. Most patients with diabetes have many years of experience of managing their own care. The purpose of this guideline is to provide detailed guidance on the peri-operative management of the surgical patient with diabetes that is specific to anaesthetists and to ensure that all current national guidance is concordant.
 
 
Modulo CEEA Leon, Gto. Curso CEEA Tijuana  XII Congreso Virtual Mexicano de Anestesiologia


          
Anestesiología y Medicina del Dolor
52 664 6848905
vwhizar@anestesia-dolor.org
anestesia-dolor.org

Copyright © 2015

E-books. Noticias


E-Books
Notificaciones semanales ⋅ 30 de septiembre de 2015
NOTICIAS


Xataka

En EEUU cada vez se venden menos ebooks, pero en España siguen en mejor forma que nunca
Xataka
Hace unos años muchos vieron en la irrupción de los libros electrónicos el principio del fin para sus hermanos de papel. Las ventas de e-books se ...



La gente ya no lee los ebooks que compra
Periodismo.com
La gente ya no lee los ebooks que compra ... presentó un informe que indica que el 60% de los ebooks adquiridos online, nunca se abrieron. Un dato ...




ABC.es

EL PIRATEO DE 'EBOOKS' HA AUMENTADO ESTA LEGISLATURA Y EL DE MÚSICA ...
Te Interesa
... - Según la última encuesta de hábitos culturales del MECD. Las descargas ilegales de libros electrónicos han crecido en los últimos cuatro años, ...
Los lectores 'digitales' se triplican en España, pero aumentan las descargas gratuitas de libros -Europa Press
El pirateo de 'ebooks' ha aumentado esta legislatura y el de música permanece estable - ecodiario
Cobertura total de la noticia




Todo eReaders (blog)

Sigil 0.9 creará ebooks en Epub3 y Epub2
Todo eReaders (blog)
Sigil grande Sigil 0.9 creará ebooks en Epub3 y Epub2 A principios del mes de junio vimos como los desarrolladores de Sigil actualizaban un plugin ...




ENTER.CO

El papel sigue vigente: ventas de los 'ebooks' bajaron 10% este año
ENTER.CO
De hecho, el panorama no es apocalíptico para las librerías, pues además de que las ventas de los 'ebooks' bajaron, desde 2010 las librerías han ...




Merca2.0

Los libros impresos están de vuelta: NYT
Merca2.0
Desde la perspectiva de negocios, el e-book no resta mercado para las librerías realmente, ya que estas también comercializan libros digitales.




Diario del Huila

Proyecto neivano preseleccionado en el Crea Digital
Diario del Huila
... multimedia, preseleccionaron 44 propuestas, 16 en la categoría de juegos de video, 10 en Animación Digital, 8 en eBooks, 10 en Juegos de Video, ...




Estrategia & Negocios

Nace Interebook, el Spotify de libros universitarios y escuelas de negocios
Estrategia & Negocios
Esta plataforma, que fue puesta en marcha por la empresa zaragozana Interebook Solutions, tiene ya más de 3.000 ebooks de materias relacionadas ...



Preseleccionados de convocatoria Crea Digital presentaron sus proyectos
Minuto30.com
Entre los que pasaron el primer corte hay 16 proyectos en la categoría de videojuegos, diez en animación digital, ocho en e-book y 14 en crossmedia.




elEconomista.es

Nace Interebook, el Spotify de los libros universitarios y de escuelas de negocios
elEconomista.es
Esta plataforma, que ha sido puesta en marcha por la empresa zaragozana Interebook Solutions, tiene ya más de 3.000 ebooks de materias ...

jueves, 1 de octubre de 2015

Mas de pancreatitis y embarazo/More on Pregnacy and pancreatitis

Octubre 1, 2015. No. 2101
Anestesia y Medicina del Dolor

Pancreatitis y embarazo
Colecistectomía laparoscópica en embarazadas: experiencia de 5 años en el Hospital General de México
Laparoscopic cholecystectomy in pregnant patient: experience in hospital General de Mexico in a period of 5 years (2008-2012)
Ginecol Obstet Mex. 2014 Aug;82(8):509-17.
Abstract
BACKGROUND: Cholecystitis is the second cause of abdominal pain during pregnancy. 1-8 of 10,000 requiring surgery, being performed in the first and second quarter laparoscopically. 100% of patients with cholecystitis, about 12% are associated with pancreatitis with high rates of maternal and fetal morbidity and mortality. OBJECTIVE: To evaluate advantages--disadvantages of maternal-fetal pregnancy laparoscopic cholecystectomy and its preventive character avoiding cases of pancreatitis. We analyze the results obtained in Perinatology Service in General Hospital of Mexico (2008 to 2012) comparing them with the current literature. MATERIAL AND METHODS: A retrospective, cross sectional, descriptive. Analyzing the following variables: maternal age, gestational age, number of gestations, surgical technique, and postoperative complications trans, maternal and perinatal morbidity, gallbladder colic episodes prior, liver ultrasound report--bile ducts, tocolytic management. RESULTS: 20 laparoscopic cholecystectomies were performed in pregnant patients. Maternal age 21-38 years, mostly multigesta. 5 patients was performed at weeks 9, 14, 20 and 25 between the SDG and 1 at 27.5 SDG.Vesicular colicky eight previous USG mostly with gallstones.Two cases of mild acute pancreatitis satisfactorily resolved. No trans or postoperative complications. Open technique for performing pneumoperitoneum (Hasson). Tocolytic management indomethacin in 100% of cases. CONCLUSIONS: The results obtained are consistent with the current literature, confirming that laparoscopic cholecystectomy is the best treatment option with minimal fetal maternal morbidity, reducing the incidence of pancreatitis and maternal- fetal consequences.
Endoscopía gastrointestinal en la embarazada
Gastrointestinal endoscopy in the pregnant woman.
World J Gastrointest Endosc. 2014 May 16;6(5):156-67. doi: 10.4253/wjge.v6.i5.156.
Abstract
About 20000 gastrointestinal endoscopies are performed annually in America in pregnant women. Gastrointestinal endoscopy during pregnancyraises the critical issue of fetal safety in addition to patient safety. Endoscopic medications may be potentially abortifacient or teratogenic. Generally, Food and Drug Administration category B or C drugs should be used for endoscopy. Esophagogastroduodenoscopy (EGD) seems to be relatively safe for both mother and fetus based on two retrospective studies of 83 and 60 pregnant patients. The diagnostic yield is about 95% when EGD is performed for gastrointestinal bleeding. EGD indications during pregnancy include acute gastrointestinal bleeding, dysphagia > 1 wk, or endoscopic therapy. Therapeutic EGD is experimental due to scant data, but should be strongly considered for urgent indications such as active bleeding. One study of 48 sigmoidoscopies performed during pregnancy showed relatively favorable fetal outcomes, rare bad fetal outcomes, and bad outcomes linked to very sick mothers. Sigmoidoscopy should be strongly considered for strong indications, including significant acute lower gastrointestinal bleeding, chronic diarrhea, distal colonic stricture, suspected inflammatory bowel disease flare, and potential colonic malignancy. Data on colonoscopy during pregnancy are limited. One study of 20 pregnant patients showed rare poor fetal outcomes. Colonoscopy is generally experimental during pregnancy, but can be considered for strong indications: known colonic mass/stricture, active lower gastrointestinal bleeding, or colonoscopic therapy. Endoscopic retrograde cholangiopancreatography (ERCP) entails fetal risks from fetal radiation exposure. ERCP risks to mother and fetus appear to be acceptable when performed for ERCP therapy, as demonstrated by analysis of nearly 350 cases during pregnancy. Justifiable indications include symptomatic or complicated choledocholithiasis, manifested by jaundice, cholangitis, gallstone pancreatitis, or dilated choledochus. ERCP should be performed by an expert endoscopist, with informed consent about fetal radiation risks, minimizing fetal radiation exposure, and using an attending anesthesiologist. Endoscopy is likely most safe during the second trimester of pregnancy.
KEYWORDS: Colonoscopy; Endoscopic complications; Endoscopic indications; Endoscopic retrograde cholangiopancreatography; Endoscopy safety; Esophagogastroduodenoscopy; Flexible sigmoidoscopy; Gastrointestinal endoscopy; Pregnancy; Teratogenicity
Colangiopancreatografía retrograda endoscópica en el embarazo. ¿Es segura?
ERCP in pregnancy: is it safe?
Gastroenterol Hepatol (N Y). 2009 Dec;5(12):851-5.
Abstract
BACKGROUND: Although rare, pancreaticobiliary disease during pregnancy can pose a serious risk to both the mother and fetus. Data regarding the relative safety of endoscopic retrograde cholangiopancreatography (ERCP) during pregnancy are sparse. METHODS: We performed a retrospective review of 17 ERCP procedures performed at a single tertiary care referral center between January 2005 and April 2009. Records were reviewed for ERCP indication, endoscopic interventions, use and extent of fluoroscopy, postprocedure complications, and pregnancy outcomes including Apgar scores. RESULTS: All procedures were performed without any maternal adverse events immediately or on follow-up. There were no signs of fetal distress during any of these cases, and there were no fetal complications noted upon delivery or at 30-day follow-up per chart review. CONCLUSION: Therapeutic ERCP during pregnancy appears to be safe when performed in experienced hands and
Eficacia y seguridad de procedimientos endoscópicos pancreatobiliares durante el embarazo
Efficacy and Safety of Pancreatobiliary Endoscopic Procedures during Pregnancy.
Gut Liver. 2015 Sep 23;9(5):672-8. doi: 10.5009/gnl14217.
Abstract
BACKGROUND/AIMS: Endoscopic therapy with endoscopic retrograde cholangiopancreatography (ERCP) has been suggested as an effective diagnostic and therapeutic tool for biliary and pancreatic disorders during pregnancy. In this report, we describe our experiences with pancreatobiliary endoscopic procedures during pregnancy. METHODS: We reviewed ERCP and endoscopic ultrasonography (EUS) procedures that were performed at a single tertiary care referral center between January 2002 and October 2013. Medical records were reviewed for the procedure indication, the duration of fluoroscopy, postprocedure complications, etc. Pregnancy outcomes and fetal complications were identified by chart review and phone calls to patients. RESULTS: A total of 10 ERCPs and five EUSs were performed in 13 pregnant patients four of whom underwent the procedure in the first trimester, eight in the second trimester, and one in the third trimester. Indications for endoscopic therapy included gallstone pancreatitis, obstructive jaundice with common bile duct (CBD) stone, asymptomatic CBD stone, pancreatic cyst, choledochal cyst, and acute cholecystitis. Only one patient had a complication, which was postprocedural hyperamylasemia. Two patients underwent an artificial abortion, one according to her own decision and the other due to an adverse drug reaction. CONCLUSIONS: ERCP seems to be effective and safe for pregnant women. Additionally, EUS can be an alternative to ERCP during pregnancy.
KEYWORDS: Cholangiopancreatography, endoscopic retrograde; Endosonography; Fetus; Pregnancy
Modulo CEEA Leon, Gto. Curso CEEA Tijuana  XII Congreso Virtual Mexicano de Anestesiologia


          
Anestesiología y Medicina del Dolor
52 664 6848905
vwhizar@anestesia-dolor.org
anestesia-dolor.org

Copyright © 2015